In­no­va­tion in the clin­ic is pick­ing up steam. How adap­tive de­signs could pave the road to per­son­al­ized med­i­cine

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

Nor­mal­ly, when you hear about in­no­va­tion in R&D, the fo­cus is on the “R” and not the “D.” There’s a ten­den­cy to as­sume that lab-based sci­en­tists do the re­al­ly cre­ative re­search, where­as clin­i­cal de­vel­op­ment is a fair­ly straight­for­ward, check-the-box­es ac­tiv­i­ty.

There’s a ker­nel of truth in this oth­er­wise un­fair as­sump­tion. Just as the ba­sic de­sign of a car hasn’t changed much from the cars our grand­par­ents drove — gas and brake ped­als, four tires, and a steer­ing wheel — clin­i­cal tri­als still have time-hon­ored fea­tures like ran­dom­iza­tion, con­trol arms and blind­ing. What is chang­ing, though, is that we’ve be­gun to aug­ment well-es­tab­lished meth­ods with in­no­va­tions that promise to make drug de­vel­op­ment faster, less ex­pen­sive and more suc­cess­ful.

One big el­e­ment in this trans­for­ma­tion is broad­er use of adap­tive study de­signs. In con­ven­tion­al clin­i­cal tri­als, the study pro­to­col is carved in stone at the out­set, and you ex­e­cute that de­sign with no de­vi­a­tions from start to fin­ish. In adap­tive tri­als, you can build flex­i­bil­i­ty in­to the pro­to­col, which al­lows you to change key pa­ra­me­ters of the study in re­sponse to in­com­ing da­ta.

Adap­tive de­signs are typ­i­cal­ly em­ployed in Phase II tri­als, where re­sults from a small group of pa­tients are used to de­cide if a much larg­er Phase III study is war­rant­ed. “Adap­tive” doesn’t mean you can make any change that seems ad­van­ta­geous—the op­tions need to be spec­i­fied in ad­vance. But if the ear­ly da­ta con­form to pre-es­tab­lished cri­te­ria, you can al­ter the size or du­ra­tion of the study, drop or add dos­es to en­sure more pa­tients re­ceive the op­ti­mal dose, or bring in more of the types of pa­tients who seem to be re­spond­ing well to the test drug.

Adap­tive mod­i­fi­ca­tions don’t change the prop­er­ties of the drug mol­e­cule be­ing test­ed, but they im­prove the odds of test­ing it in the right pa­tients, at the right dose, for the right du­ra­tion to show its risks and ben­e­fits. Greater clar­i­ty can re­duce the risk of false-pos­i­tive or false-neg­a­tive re­sults. A false pos­i­tive — think­ing a drug works when it doesn’t — can lead a com­pa­ny to in­vest heav­i­ly in a large study that will ul­ti­mate­ly fail to de­liv­er what pa­tients need. A false neg­a­tive can cast doubt on the val­ue of a ther­a­py and ter­mi­nate de­vel­op­ment of an in­ves­ti­ga­tion­al drug with re­al ben­e­fits for pa­tients Ul­ti­mate­ly, adap­tive de­signs can al­low us to more read­i­ly achieve a per­son­al­ized med­i­cine, in which pa­tients most like­ly to ben­e­fit from a drug are the ones to re­ceive it.

The ba­sic idea of adap­tive clin­i­cal tri­al de­signs isn’t new — clin­i­cal sci­en­tists from acad­e­mia and in­dus­try have been study­ing this con­cept for two decades. But for much of that time, these meth­ods were seen as too un­proven and risky. Sev­er­al years ago, Am­gen de­cid­ed there was more risk in not adopt­ing these new ap­proach­es, which have the po­ten­tial to de­liv­er more suc­cess­ful stud­ies more quick­ly and with low­er de­vel­op­ment costs.

In con­ven­tion­al tri­als, this trio of pri­or­i­ties — cost, speed, and like­li­hood of suc­cess — in­volve trade-offs that make it hard to pur­sue all three goals si­mul­ta­ne­ous­ly. For ex­am­ple, to boost the like­li­hood of suc­cess, you nor­mal­ly need to col­lect more da­ta from more pa­tients, which trans­lates in­to added time and ex­pense. But im­ple­ment­ed cor­rect­ly, adap­tive de­signs can po­ten­tial­ly avoid these trade­offs and fa­cil­i­tate small­er and faster tri­als that re­veal a drug’s true po­ten­tial with more pre­ci­sion.

Two de­vel­op­ments are ac­cel­er­at­ing the trend to­ward adap­tive de­signs. First, the FDA is en­cour­ag­ing clin­i­cal in­no­va­tion and part­ner­ing with com­pa­nies that are will­ing to try new ap­proach­es. For ex­am­ple, Am­gen has an in­ves­ti­ga­tion­al ther­a­py for lu­pus, efavaleukin al­fa (for­mer­ly AMG 592), which is par­tic­i­pat­ing in the FDA’s Com­plex In­no­v­a­tive Tri­al De­sign (CID) Pi­lot Pro­gram. We plan to use an adap­tive de­sign to work to ze­ro in on the op­ti­mal dose and to en­sure more pa­tients re­ceive this op­ti­mal dose to in­crease the like­li­hood that the right dose is se­lect­ed for fu­ture stud­ies.

A re­lat­ed de­vel­op­ment has been greater ac­cess to re­al-world da­ta and ad­vances in com­pu­ta­tion­al meth­ods that use these da­ta to sim­u­late clin­i­cal tri­als. Sim­u­la­tions can’t pre­dict how a drug will per­form in an ac­tu­al clin­i­cal study, but they can show how dif­fer­ent study de­signs are ex­pect­ed to per­form un­der dif­fer­ent sce­nar­ios.

In de­sign­ing any tri­al, you need to make as­sump­tions about a whole range of vari­ables — the ef­fect size of the drug you are test­ing; how long it takes for this ef­fect to emerge; the re­sponse rate to the place­bo or com­para­tor drugs, etc. For our study in lu­pus pa­tients, we ran mil­lions of sim­u­la­tions, plug­ging in dif­fer­ent val­ues for these vari­ables and oth­ers, with the goal of find­ing the de­sign op­tions most like­ly to yield re­li­able re­sults.

In­no­v­a­tive de­signs ex­tend to tri­als where the drug it­self is the el­e­ment that is open to mod­i­fi­ca­tion. The COVID-19 pan­dem­ic has un­der­scored the im­por­tance of speed in drug de­vel­op­ment, and adap­tive plat­form tri­als pro­vide a way to rapid­ly test mul­ti­ple po­ten­tial ther­a­pies us­ing a sin­gle pro­to­col.

As part of the COVID R&D Al­liance, Am­gen is part­ner­ing with Take­da and UCB in the COM­MU­NI­TY study, which will ini­tial­ly test three po­ten­tial treat­ments for pa­tients hos­pi­tal­ized with COVID-19. The de­sign is ef­fi­cient be­cause it us­es same en­try cri­te­ria for all agents be­ing eval­u­at­ed, and it em­ploys a com­mon con­trol arm and a com­mon fu­til­i­ty bar to eval­u­ate for ef­fi­ca­cy. Test drugs can be dropped from the tri­al if they show lack of ef­fi­ca­cy, and new agents can be in­tro­duced quick­ly to take ad­van­tage of the es­tab­lished pro­to­col.

Am­gen is us­ing a sim­i­lar con­cept to in­ves­ti­gate so­tora­sib, a po­ten­tial new tar­get­ed ther­a­py for pa­tients with non-small cell lung can­cer who car­ry a mu­tat­ed gene known as KRAS G12C. Many of these pa­tients have failed to re­spond to stan­dard ther­a­pies, so there is an ur­gent need to eval­u­ate oth­er po­ten­tial treat­ment op­tions rapid­ly. To ac­cel­er­ate test­ing of so­tora­sib in com­bi­na­tion with oth­er can­cer ther­a­pies, we es­tab­lished a 10-arm mas­ter pro­to­col with a high­ly flex­i­ble de­sign. The goal is to de­tect any pos­i­tive ef­fi­ca­cy sig­nals as ear­ly as pos­si­ble, so that the most promis­ing com­bi­na­tions can be quick­ly iden­ti­fied and ex­pand­ed in­to larg­er stud­ies.

Clin­i­cal in­no­va­tion isn’t on­ly a smarter way to do drug de­vel­op­ment, it is bet­ter for pa­tients as well. The soon­er we can de­ter­mine whether an in­ves­ti­ga­tion­al ther­a­py or spe­cif­ic dose works or not, the soon­er we can ei­ther ad­vance that ther­a­py or stop test­ing it in pa­tients. Speed and clar­i­ty are im­por­tant in re­search, but even more im­por­tant to pa­tients search­ing for the right treat­ment for their dis­ease.

Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

Boehringer Ingelheim has quietly shut down a small Phase II study for one of its lead drugs.

The private pharma player confirmed to Endpoints News that it had shuttered a study testing spesolimab as a therapy for Crohn’s patients suffering from bowel obstructions.

A spokesperson for the company tells Endpoints:

Taking into consideration the current therapeutic landscape and ongoing clinical development programs, Boehringer Ingelheim decided to discontinue our program in Crohn’s disease. It is important to note that this decision is not based on any safety findings in the clinical trials.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vas Narasimhan (Photographer: Jason Alden/Bloomberg via Getty Images)

No­var­tis de­tails plans to axe 8,000 staffers as Narasimhan be­gins sec­ond phase of a glob­al re­org

We now know the number of jobs coming under the axe at Novartis, and it isn’t small.

The pharma giant is confirming a report from Swiss newspaper Tages-Anzeiger that it is chopping 8,000 jobs out of its 108,000 global staffers. A large segment will hit right at company headquarters in Basel, as CEO Vas Narasimhan axes some 1,400 of a little more than 11,000  jobs in Switzerland.

The first phase of the work is almost done, the company says in a statement to Endpoints News. Now it’s on to phase two. In the statement, Novartis says:

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

Lina Gugucheva, NewAmsterdam Pharma CBO

Phar­ma group bets up to $1B-plus on the PhI­II res­ur­rec­tion of a once dead-and-buried LDL drug

Close to 5 years after then-Amgen R&D chief Sean Harper tamped the last spade of dirt on the last broadly focused CETP cholesterol drug — burying their $300 million upfront and the few remaining hopes for the class with it — the therapy has been fully resurrected. And today, the NewAmsterdam Pharma crew that did the Lazarus treatment on obicetrapib is taking another big step on the comeback trail with a €1 billion-plus regional licensing deal, complete with close to $150 million in upfront cash.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

How pre­pared is bio­phar­ma for the cy­ber dooms­day?

One of the largest cyberattacks in history happened on a Friday, Eric Perakslis distinctly remembers.

Perakslis, who was head of Takeda’s R&D Data Sciences Institute and visiting faculty at Harvard Medical School at the time, had spent that morning completing a review on cybersecurity for the British Medical Journal. Moments after he turned it in, he heard back from the editor: “Have you heard what’s going on right now?”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

(AP Photo/Gemunu Amarasinghe)

Some phar­ma com­pa­nies promise to cov­er abor­tion-re­lat­ed trav­el costs — while oth­ers won't go that far yet

As the US Department of Health and Human Services promises to support the millions of women who would now need to cross state lines to receive a legal abortion, a handful of pharma companies have said they will pick up employees’ travel expenses.

GSK, Sanofi, Johnson & Johnson, BeiGene, Alnylam and Gilead have all committed to covering abortion-related travel expenses just four days after the Supreme Court overturned Roe v. Wade and revoked women’s constitutional right to an abortion.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

Aurobindo Pharma co-founders P. V. Ram Prasad Reddy (L) and K. Nityananda Reddy

Au­robindo Phar­ma re­ceives warn­ing let­ter from In­di­a's SEC fol­low­ing more FDA ques­tion marks

Indian-based generics manufacturer Aurobindo Pharma has been in the crosshairs of the FDA for several years now, but the company is also attracting attention from regulators within the subcontinent.

According to the Indian business news site Business Standard, a warning letter was sent to the company from the Securities Exchange Board of India, or SEBI.

The letter is related to disclosures made by the company on an ongoing FDA audit of the company’s Unit-1 API facility in Hyderabad, India as well as observations made by the US regulator between 2019 and 2022.

New Charles River Laboratories High Quality (HQ) Plasmid DNA Centre of Excellence at Bruntwood SciTech’s Alderley Park in Cheshire, United Kingdom. (Charles River)

Charles Riv­er Lab­o­ra­to­ries to start cell and gene ther­a­py man­u­fac­tur­ing at UK site in Sep­tem­ber

While Massachusetts-based Charles River Laboratories has been on an acquisition spree, they are not against planting their flag. The latest move by the company sees them crossing the pond to establish a manufacturing site in the UK.

The company on Tuesday opened its cell and gene therapy manufacturing center at Bruntwood SciTech’s Alderley Park in Cheshire, United Kingdom. The expansion follows Charles River’s acquisition of Cognate BioServices and Cobra Biologics in 2021 for $875 million. Cognate is a plasmid DNA, viral vector and cell therapy CDMO.

Bristol Myers Squibb (Alamy)

CVS re­sumes cov­er­age of block­buster blood thin­ner af­ter price drop fol­lows Jan­u­ary ex­clu­sion

Following some backlash from the American College of Cardiology and patients, Bristol Myers Squibb and Pfizer lowered the price of their blockbuster blood thinner Eliquis, thus ensuring that CVS Caremark would cover the drug after 6 months of it being off the major PBM’s formulary.

“Because we secured lower net costs for patients from negotiations with the drug manufacturer, Eliquis will be added back to our template formularies for the commercial segment effective July 1, 2022, and patient choices will be expanded,” CVS Health said in an emailed statement. “Anti-coagulant therapies are among the non-specialty products where we are seeing the fastest cost increases from drug manufacturers and we will continue to push back on unwarranted price increases.”

#Can­nes­Lions2022: Con­sumer health ex­ecs call on agen­cies to in­volve pa­tients in cre­ative process

CANNES — When Tamara Rogers joined GSK back in 2018, “science was king and R&D were the gods.” Now the global chief marketing officer of consumer healthcare wants to make room for another supreme being: the consumer.

As health and wellness becomes more relevant to consumers amid the pandemic, four health-focused executives called on marketers to involve patients in their creative process in a panel discussion at the Cannes Lions advertising creativity festival.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.